What's Happening?
CSL Behring is actively recruiting for a Director, HAE / ANDEMBRY Brand Lead, to spearhead the development and implementation of the HAE disease-area and ANDEMBRY brand strategy for the international region. This role is critical for driving sustainable
growth through market expansion, brand adoption, and launch excellence. The Director will be responsible for shaping the complementary positioning of ANDEMBRY and BERINERT within the HAE portfolio, ensuring a consistent international direction that can be adapted to diverse local market needs. Key responsibilities include leading the development of the HAE disease-area and ANDEMBRY brand strategy, acting as a marketing subject-matter expert for affiliates, and leading the ANDEMBRY International Brand Team (IBT). The position requires at least 10 years of healthcare experience, with a minimum of 8 years in pharmaceutical or biotechnology sales and marketing, and a demonstrated ability to establish disease-area, portfolio, and brand strategy.
Why It's Important?
This recruitment highlights CSL Behring's strategic focus on expanding its presence and market share in the international HAE (hereditary angioedema) treatment landscape. The emphasis on a dedicated brand lead for ANDEMBRY and BERINERT underscores the company's commitment to these specific therapies and their importance within its portfolio. The role's international scope suggests a concerted effort to standardize and optimize marketing and sales efforts across various global markets, which can lead to more efficient resource allocation and stronger brand recognition. For patients with HAE, this could mean improved access to treatments and more consistent information about available therapies. For the pharmaceutical industry, it reflects the ongoing trend of specialized roles focused on specific disease areas and brand management, particularly in the competitive rare disease market. The successful candidate will play a pivotal role in influencing market dynamics and patient access to critical medications.
What's Next?
The successful appointment of the Director, HAE / ANDEMBRY Brand Lead, will likely lead to a more unified and aggressive international strategy for CSL Behring's HAE portfolio. This could involve new marketing campaigns, enhanced educational initiatives for healthcare providers, and expanded market access programs in various countries. The role's focus on shaping the complementary positioning of ANDEMBRY and BERINERT suggests a strategic effort to maximize the impact of both drugs, potentially through differentiated messaging or combined treatment approaches. This could also influence competitor strategies in the HAE market, as other pharmaceutical companies may respond with their own enhanced international marketing efforts. Ultimately, the outcome of this strategic hire will be measured by the sustained growth of the HAE portfolio and the increased adoption of ANDEMBRY and BERINERT in international markets.
